Humacyte, Inc.
NASDAQ:HUMABiotechnology
-$0.03 today
- Market cap
- $139.18M
- Beta
- 2.46
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.49
Volume 4.34M
Average 8.14M
HUMA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Humacyte, Inc.NASDAQ: HUMA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$13.56M, compared with $43.97M a year earlier. Trailing-twelve-month EBITDA was -$79.77M.
Context
- EBITDA amounted to 1091.2% of revenue in FY2025.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$76.86M (-245.6%) for the fiscal year ending Dec 2026, a slowdown from the +83.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.56M+31.9% QoQ
- Last fiscal yearDec 2025
- -$22.24M+83.2% YoY
- LTMMar 2026
- -$79.77M-33.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -130.8% | +17.6% | +148.4 pp |
| 1 year | +83.2% | -245.6% | -328.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (22.24M) USD
- Year-over-year change
- +83.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.24M) | +83.2% |
| FY2024 | 2024-12-31 | (132.23M) | -37.1% |
| FY2023 | 2023-12-31 | (96.46M) | -4045.1% |
| FY2022 | 2022-12-31 | 2.45M | +117.6% |
| FY2021 | 2021-12-31 | (13.89M) | — |
EBITDA vs competitors
How HUMA compares with its peers on the latest reported figures
- HUMA's LTM Mar 2026 EBITDA of -$79.77M is the 7th highest of the 11 companies compared; the peer median is -$70.03M.
- Its year-over-year change of -33.1% is the 8th highest of 11, against a peer median of -9.1%.
- EBITDA amounts to 3956.7% of revenue for HUMA, versus a peer median of 257.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$46.14M | +19.2% | — | — |
| LTM Mar 2026 | -$50.77M | +11.7% | — | — | |
| LTM Mar 2026 | -$50.86M | -14.6% | — | — | |
| LTM Mar 2026 | -$58.85M | +7.0% | — | — | |
| LTM Mar 2026 | -$67.53M | -3.7% | — | 148.9% | |
| LTM Mar 2026 | -$72.53M | +7.7% | — | 257.0% | |
| LTM Mar 2026 | -$79.77M | -33.1% | — | 3956.7% | |
| LTM Mar 2026 | -$112.54M | -37.5% | — | 308.4% | |
| LTM Mar 2026 | -$136.24M | -213.5% | — | 62.6% | |
| LTM Mar 2026 | -$164.87M | -697.5% | — | 2873.3% | |
| LTM Mar 2026 | -$179.89M | -30.1% | — | — | |
| Peer median (excluding HUMA) | -$70.03M | -9.1% | — | 257.0% | |
Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.26M | 1.57M | 0 | 0 | 2.04M |
| Cost of Revenue | 61.34M | 8.26M | 76.55M | 7.19M | 17.05M |
| Gross Profit | (60.08M) | (6.69M) | (76.55M) | (7.19M) | (15.01M) |
| Gross Margin | -4756.8% | -427.5% | — | — | -736.5% |
| Research & Development | 61.34M | 63.26M | 76.55M | 88.6M | 69.3M |
| Selling, General & Admin | 21.13M | 22.88M | 20.39M | 25.8M | 31.17M |
| Operating Expenses | 21.13M | 77.89M | 23.5M | 107.21M | 92.43M |
| Depreciation & Amortization | 8.24M | 8.21M | 7.72M | 7.19M | 7.35M |
| EBITDA | (13.89M) | 2.45M | (96.46M) | (132.23M) | (22.24M) |
| EBITDA Margin | -1099.6% | 156.2% | — | — | -1091.2% |
| Operating Income | (81.21M) | (84.58M) | (100.05M) | (114.4M) | (107.44M) |
| Operating Margin | -6429.8% | -5404.3% | — | — | -5271.7% |
| Interest Income | 16K | 2.63M | 5.47M | 4.1M | 2.59M |
| Interest Expense | 4.35M | 6.2M | 6.6M | 9.28M | 11.25M |
| Other Income / Expenses | 54.73M | 72.61M | (10.73M) | (34.3M) | 66.6M |
| Income Before Tax | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Pre-Tax Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Net Margin | -2096.4% | -764.5% | — | — | -2003.6% |
| EPS (Basic) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| EPS (Diluted) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) |
| Weighted Avg Shares | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
| Weighted Avg Shares (Diluted) | 39.97M | 103.05M | 103.42M | 118.48M | 158.16M |
Humacyte, Inc.
NASDAQ:HUMA
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.